Document:

Exhibit

EXHIBIT 10.4

GUARANTY SUPPLEMENT
To the Holders of the Series A Notes, (each, as
hereinafter defined) of STERIS Corporation
(the “Company”)

Ladies and Gentlemen:
    
WHEREAS, in order to obtain funds for the purposes set forth in Schedule 5.14 to the
Note Purchase Agreement, the Company entered into that certain Note Purchase Agreement
dated as of May 15, 2015 (the “Note Purchase Agreement”) between the Company and
each of the Holders as defined therein providing for, inter alia, the issue and sale by the
Company of (a) $125,000,000 aggregate principal amount of its 3.45% Senior Notes, Series
A-1, due May 14, 2025 (the “Series A-1 Notes”), (b) $125,000,000 aggregate principal amount
of its 3.55% Senior Notes, Series A-2, due May 14, 2027 (the “Series A-2 Notes”), and (c)
$100,000,000 aggregate principal amount of its 3.70% Senior Notes, Series A-3, due May
14, 2030 (the “Series A-3 Notes”; the Series A-1 Notes, the Series A-2 Notes and the Series
A-3 Notes are hereinafter referred to as the “Series A Notes”). Each Holder of a Note shall be
referred to as a “Holder”.

WHEREAS, as a condition precedent to the entering into the Note Purchase Agreement
by the Holders, the Holders required that certain affiliates of the Company enter into an
Affiliate Guaranty as security for the Notes (the “Guaranty”).

Pursuant to Section 9.7 of the Note Purchase Agreement, the Company has agreed to
cause the undersigned, Synergy Health AST, LLC, a limited liability company organized under the laws of Delaware, Synergy Health US Holdings, Inc., a corporation organized under the laws of Delaware, and Synergy Health North America, Inc., a corporation organized under the laws of Florida  (the “Additional Guarantors”), to join in the Guaranty. In accordance with the requirements of the Guaranty, the Additional Guarantors desire to amend the definition of Guarantor (as the same may have been heretofore amended) set forth in the Guaranty attached hereto so that at all times from and after the date hereof, the Additional Guarantors shall be jointly and severally liable as set forth in the Guaranty for the obligations of the Company under the Note Purchase Agreement and Notes to the extent and in the manner set forth in the Guaranty.

The undersigned is the duly elected President of each of the Additional Guarantors, each a subsidiary of the Company, and is duly authorized to execute and deliver this Guaranty Supplement to each of you. The execution by the undersigned of this Guaranty Supplement shall evidence their consent to and acknowledgment and approval of the terms set forth herein and in the Guaranty and by such execution the Additional Guarantors shall be deemed to have made in favor of the Holders the representations and warranties set forth in Section 5 of the Guaranty.

Upon execution of this Guaranty Supplement, the Guaranty shall be deemed to be

    

amended as set forth above. Except as amended herein, the terms and provisions of the Guaranty
are hereby ratified, confirmed and approved in all respects.

Any and all notices, requests, certificates and other instruments (including the Notes) may refer to the Guaranty without making specific reference to this Guaranty Supplement, but nevertheless all such references shall be deemed to include this Guaranty Supplement unless the context shall otherwise require.
    

Dated: August 8, 2017

SYNERGY HEALTH AST, LLC

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

SYNERGY HEALTH US HOLDINGS, INC.

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

SYNERGY HEALTH NORTH AMERICA, INC.

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

ACCEPTED AND AGREED:

STERIS CORPORATION

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   Senior Vice President and Chief Financial Officer

[Signature Page to 2015 Guaranty Supplement - Joinder of Synergy Health]Exhibit

EXHIBIT 10.5

GUARANTY SUPPLEMENT
To the Holders of the Series A-1 Notes, 
the Series A-2 Notes, the Series A-3 Notes, 
the Series A-4 Notes, the Series A-5 Notes, 
the Series A-6 Notes, and the Series A-7 Notes
 (each, as hereinafter defined) of STERIS plc (the “Company”)

Ladies and Gentlemen:
    
WHEREAS, in order to obtain funds for the purposes set forth in Schedule 5.14 to the Note Purchase Agreement, the Company entered into that certain Note Purchase Agreement dated as of January 23, 2017 (the “Note Purchase Agreement”) among the Company and each of the Holders as defined therein  providing for, inter alia, the issue and sale by the Company of (a) $50,000,000 aggregate principal amount of its 3.93% Senior Notes, Series A‐1, due February 27, 2027 (the “Series A‐1 Notes”); (b) €60,000,000 aggregate principal amount of its 1.86% Senior Notes, Series A‐2, due February 27, 2027 (the “Series A‐2 Notes”); (c) $45,000,000 aggregate principal amount of its 4.03% Senior Notes, Series A‐3, due February 27, 2029 (the “Series A‐3 Notes”); (d) €20,000,000 aggregate principal amount of its 2.04% Senior Notes, Series A‐4, due February 27, 2029 (the “Series A‐4 Notes”); (e) £45,000,000 aggregate principal amount of its 3.04% Senior Notes, Series A‐5, due February 27, 2029 (the “Series A‐5 Notes”); (f) €19,000,000 aggregate principal amount of its 2.30% Senior Notes, Series A‐6, due February 27, 2032 (the “Series A‐6 Notes”); and (g) £30,000,000 aggregate principal amount of its 3.17% Senior Notes, Series A‐7, due February 27, 2032 (the “Series A‐7 Notes”; the Series A‐1 Notes, the Series A‐2 Notes, the Series A‐3 Notes, the Series A-4 Notes, the Series A-5 Notes, the Series A-6 Notes and the Series A-7 Notes are hereinafter referred to as the “Series A Notes”; and together with any Supplemental Notes issued pursuant to Section 1.2 of the Note Purchase Agreement, the “Notes”).  Each holder of a Note shall be referred to as a “Holder”.

WHEREAS, as a condition precedent to the entering into the Note Purchase Agreement
by the Holders, the Holders required that certain affiliates of the Company enter into an Affiliate Guaranty as security for the Notes (the “Guaranty”).

Pursuant to Section 9.7 of the Note Purchase Agreement, the Company has agreed to
cause the undersigned, Synergy Health AST, LLC, a limited liability company organized under the laws of Delaware, Synergy Health US Holdings, Inc., a corporation organized under the laws of Delaware, and Synergy Health North America, Inc., a corporation organized under the laws of Florida  (the “Additional Guarantors”), to join in the Guaranty. In accordance with the requirements of the Guaranty, the Additional Guarantors desire to amend the definition of Guarantor (as the same may have been heretofore amended) set forth in the Guaranty attached hereto so that at all times from and after the date hereof, the Additional Guarantors shall be jointly and severally liable as set forth in the Guaranty for the obligations of the Company under 

    

the Note Purchase Agreement and Notes to the extent and in the manner set forth in the Guaranty.

The undersigned is the duly elected President of each of the Additional Guarantors, each a subsidiary of the Company, and is duly authorized to execute and deliver this Guaranty Supplement to each of you. The execution by the undersigned of this Guaranty Supplement shall evidence their consent to and acknowledgment and approval of the terms set forth herein and in the Guaranty and by such execution the Additional Guarantors shall be deemed to have made in favor of the Holders the representations and warranties set forth in Section 5 of the Guaranty.

Upon execution of this Guaranty Supplement, the Guaranty shall be deemed to be
amended as set forth above. Except as amended herein, the terms and provisions of the Guaranty
are hereby ratified, confirmed and approved in all respects.

Any and all notices, requests, certificates and other instruments (including the Notes) may refer to the Guaranty without making specific reference to this Guaranty Supplement, but nevertheless all such references shall be deemed to include this Guaranty Supplement unless the context shall otherwise require.
    

Dated: August 8, 2017

SYNERGY HEALTH AST, LLC

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

SYNERGY HEALTH US HOLDINGS, INC.

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

SYNERGY HEALTH NORTH AMERICA, INC.

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   President

ACCEPTED AND AGREED:

STERIS PLC

By:     /s/ Michael J. Tokich                                   

Name: Michael J. Tokich
Title:   Senior Vice President and Chief Financial Officer 

[Signature Page to 2017 Guaranty Supplement]Exhibit

EXHIBIT 10.6

Description of STERIS plc Non-Employee Director Compensation Program

Summarized below is the Director compensation program for STERIS plc (“STERIS”) non-employee Directors for the term of office beginning August 1, 2017 and subsequent terms.

An annual retainer of $340,000 is payable to the Chairman of the Board and an annual retainer of $240,000 is payable to each other non-employee Director. The retainer fees are payable in full at the beginning of each Director’s term. Retainer fees are fully vested immediately, regardless of the form in which paid.

For the term of office beginning August 1, 2017 the retainer fee is payable as follows: $65,000 in cash ($105,000 for the Chairman), $67,500 in stock options ($97,500 for the Chairman) and $67,500 in career restricted stock units (“CRSUs”) ($97,500 for the Chairman). Each Director may elect to receive all or a part of the cash or option portions of the foregoing fee in STERIS shares or CRSUs and may elect to receive all or part of the CRSU portion of the foregoing fee in STERIS shares.  The remaining $40,000 of the retainer fee for the term of office beginning in 2017 is payable as follows: $20,000 in stock options and $20,000 in CRSUs. 

For the term of office beginning in 2018, the retainer fee will be as follows: $65,000 in cash ($105,000 for the Chairman), $87,500 in stock options ($117,500 for the Chairman) and $87,500 in career restricted stock units (“CRSUs”) ($117,500 for the Chairman).  Each Director may elect to receive all or a part of the cash or option portions of the fee in STERIS shares or CRSUs and may elect to receive all or part of the CRSU portion of the fee in STERIS shares.

Notwithstanding the foregoing, the available forms of payment for Directors who have not satisfied the Company’s Non-Employee Director Stock Ownership Guidelines are limited until such time as those Guidelines have been satisfied. A Director who has not met the Guidelines will receive a retainer fee of $65,000 in cash, with the remaining portion of such Director’s retainer fee payable in CRSUs.  The Director also may elect to receive additional CRSUs in lieu of all or part of the cash portion of the fee.

Permitted elections for incumbent Directors are required to be made on or before the December 31 that immediately precedes the beginning of the term for which the compensation will be paid.

The number of CRSUs or STERIS shares a Director is entitled to receive is determined based upon the dollar amount of the retainer fees elected to be received in CRSUs or STERIS shares, and the NYSE STERIS per share closing price on the effective date of grant. The number of options a Director is entitled to receive is determined based upon the same factors and a Black-Scholes calculation, and the option price is the NYSE per share closing price on the effective date of grant.

A Director’s CRSU’s will be settled in STERIS ordinary shares six months after the cessation of the Director’s Board service. Directors will be paid cash dividend equivalents on their CRSUs as dividends are paid on STERIS ordinary shares.

Effective for the term of office beginning August 1, 2017 Annual Committee Chair fees are payable in the following amounts, with payments to be made at the beginning of each term: $20,000 for the Audit Committee Chair and $15,000 for the other Committee Chairs. Meeting fees are payable at a rate of $1,000 per meeting for Board meetings and assigned Committee meetings attended in excess of 20 during the annual term.

The STERIS Director compensation program for non-employee Directors may be modified by the Board of Directors.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]